Ontology highlight
ABSTRACT:
SUBMITTER: Zhu Y
PROVIDER: S-EPMC7240069 | biostudies-literature | 2020
REPOSITORIES: biostudies-literature
Zhu Yanlin Y Xu Shuangshuang S Lu Yi Y Wei Yijuan Y Yao Benqiang B Guo Fusheng F Zheng Xing X Wang Yumeng Y He Ying Y Jin Lihua L Li Yong Y
Frontiers in pharmacology 20200514
Non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disorder, and yet with no pharmacological treatment approved worldwide. The repositioning of old drugs provides a safe approach for drug development. Vidofludimus, an inhibitor for dihydroorotate dehydrogenase (DHODH) for the treatment of autoimmune disorders, is herein uncovered as a novel modulator for farnesoid X receptor (FXR) by biochemical and crystallographic analysis. We further revealed that vidofludimus ...[more]